516-P: Preventive Effect of Sulforaphane on Type 2 Diabetes-Induced Diabetic Nephropathy via AMPK-Mediated Activation of Glucose/Lipid Metabolism and Nrf2 Antioxidative Function

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 516-P
Author(s):  
ZHUO LI ◽  
LU CAI ◽  
YIKE SUN
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Lipid Metabolism ◽  
Preventive Effect ◽  
Antioxidative Function

scholarly journals Lipid metabolism and levels of proinflammatory cytokines in patients with type 2 diabetes with diabetic nephropathy depending on the stage of chronic kidney disease

2012 ◽  
Vol 9 (2) ◽  
pp. 53-56
Author(s):  
Y V Khasanova ◽  
A B Galkina ◽  
A A Nelaeva ◽  
I V Medvedeva
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Diabetic Nephropathy ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Proinflammatory Cytokines ◽  
Diabetes Development ◽  
Lipid Abnormalities ◽  
Relationship Of

Aim: to study the role and relationship of lipid metabolism and levels of proinflammatory cytokines in patients with type 2 diabetes mellitus (DM2) with diabetic nephropathy (DN), depending on the stage of chronic kidney disease (CKD). Materials and Methods: a total of 240 patients with type 2 diabetes in the early stages of DN and CKD were studied. Results: in patients with type 2 diabetes development of DN was associated with an increased level of proinflammatory cytokines and lipid abnormalities (hypertriglyceridemia). We found a negative correlation between the level of triglycerides (TG) and glomerular filtration rate (GFR) (r = -0,43) and a direct correlation between the level of IL-6 and TG (r = 0,48). Conclusions: increased levels of proinflammatory cytokines and triglycerides increase the risk of development and progression of DN and CKD.

scholarly journals Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function

2020 ◽  
Vol 134 (18) ◽  
pp. 2469-2487
Author(s):  
Zhuo Li ◽  
Hua Guo ◽  
Jia Li ◽  
Tianjiao Ma ◽  
Shanshan Zhou ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Lipid Metabolism ◽  
Glycogen Synthase ◽  
Normal Diet ◽  
Renal Hypertrophy ◽  
Antioxidative Function ◽  
Urine Albumin ◽  
Induce Insulin Resistance ◽  
Gsk 3Β

Abstract Sulforaphane (SFN) prevents diabetic nephropathy (DN) in type 2 diabetes (T2D) by up-regulating nuclear factor (erythroid-derived 2)-like 2 (Nrf2). AMP-activated protein kinase (AMPK) can attenuate the pathogenesis of DN by improving renal lipotoxicity along with the activation of Nrf2-mediated antioxidative signaling. Therefore, we investigated whether AMPKα2, the central subunit of AMPK in energy metabolism, is required for SFN protection against DN in T2D, and whether potential cross-talk occurs between AMPKα2 and Nrf2. AMPKα2 knockout (Ampkα2−/−) mice and wildtype (WT) mice were fed a high-fat diet (HFD) or a normal diet (ND) to induce insulin resistance, followed by streptozotocin (STZ) injection to induce hyperglycemia, as a T2D model. Both T2D and control mice were treated with SFN or vehicle for 3 months. At the end of the 3-month treatment, all mice were maintained only on HFD or ND for an additional 3 months without SFN treatment. Mice were killed at sixth month after T2D onset. Twenty-four-hour urine albumin at third and sixth months was significantly increased as renal dysfunction, along with significant renal pathological changes and biochemical changes including renal hypertrophy, oxidative damage, inflammation, and fibrosis in WT T2D mice, which were prevented by SFN in certain contexts, but not in Ampkα2−/− T2D mice. SFN prevention of T2D-induced renal lipotoxicity was associated with AMPK-mediated activation of lipid metabolism and Nrf2-dependent antioxidative function in WT mice, but not in SFN-treated Ampkα2−/− mice. Therefore, SFN prevention of DN is AMPKα2-mediated activation of probably both lipid metabolism and Nrf2 via AMPK/AKT/glycogen synthase kinase (GSK)-3β/Src family tyrosine kinase (Fyn) pathways.

2306-PUB: Long-Term Effect of Liraglutide on the Prevention of Progression of Diabetic Nephropathy in Elderly Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2306-PUB
Author(s):  
MAMI YOSHIDA ◽  
AI YOSHIDA ◽  
ERIKO OH ◽  
NAOMUNE YAMAMOTO ◽  
EUN SASAKI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Elderly Patients ◽  
Term Effect ◽  
Long Term Effect
Sign in / Sign up

Export Citation Format

Share Document